Every place here, they were like, ‘Oh, sorry, we’re full.’ And they had about a year’s long waiting list for memory care.” ...

The North Carolina Community Foundation has received a $7.5 million grant from Lilly Endowment Inc. to support its long-term ...

Enjoying the parade from the picturesque sidewalks of North Union Street ... Ceremony is presented by Eli Lilly on Friday, Nov. 22, from 6-8:30 p.m. in downtown Concord. At the tree lighting ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

It's the same story with stocks. We saw that happen with Eli Lilly (NYSE: LLY) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other S&P 500 stocks. As per AXA Investment Managers, the US dominated financial markets this ...

What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Dark Sky Films has acquired all North American rights to the psychological horror Lilly Lives Alone from Yellow Veil Pictures, which will represent international sales at next week’s AFM in Las ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE:LLY) for a little while now. My first article about the company, published in ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of analyst coverage. GLP-1 adoption has fueled Lilly’s ...